Observation on Efficacy and Safety to Treat Severe Nonproliferative Diabetes Retinopathy in Young People Jointly with Leizumab and Retinal Laser Photocoagulation
Objective To explore the value to treat severe nonproliferative diabetes retinopathy in young people jointly with Leizumab and retinal laser photocoagulation.Methods Totally 74 young patients with severe nonproliferative diabetes retinopathy treated between Sep.2022 and Sep.2023 were selected and divided randomly into a control group and an observation group,37 patients in each group.The patients in the control group were given 3-4 sessions of retinal laser photocoagulation at an interval of 7 days(laser exposure time:100-300 ms,power:100-200 mW and spot diameter:100-200 pm).For the observation group,one week before the retinal laser photocoagulation,the patients were given intravitreal injection of 0.05 mg/0.05 ml ranibizumab.The average thickness of the macular fovea,best corrected visual acuity and overall volume of the 6mm diameter neuroepithelium in the macular area were measured respectively before the treatment and 1 and 3 months after the last photocoagulation for each patient.For all the patients,the duration of each symptom induced,including fundus hemorrhage,fundus exudate and retinal edema,and the incidence of such complications as visual impairment,edema and bleeding were recorded.Result Before the treatment,there was no significant difference in the average thickness of the macular fovea,BCVA and overall volume of the 6mm diameter neuroepithelium in the macular area between the two groups of patients(P＞0.05).The average thickness of the macular fovea and the overall volume of the 6mm diameter neuroepithelium in the macular area were smaller in the observation group than in the control group at different time points after the treatment,and the BCVA in the observation group was higher than that in the control group(P＜0.05).For the observation group,the duration of bleeding,retinal edema and retinal exudate lasted for 2.56±0.4 weeks,5.21±0.7 weeks and 9.45±1.4 weeks respectively,which were shorter than those in the control group(P＜0.05).The incidence(5.41％)of complications in the observation group was lower than that(24.3％)in the control group,and the difference was statistically significant(P＜0.05).Conclusions For young patients with severe nonproliferative diabetes retinopathy,the combined treatment with Leizumab and retinal laser photocoagulation will significantly improve their visual acuity,shorten the duration of their symptoms and significantly reduce the incidence of related complications.It is hence recommended for clinical promotion.
Retinal laser photocoagulationLeizumabSevere nonproliferative diabetes retinopathy in young people
NETL
NSTL
万方数据
